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	Noonan Syndrome with Multiple Lentigines (NSML) is a rare genetic disease resulting in a phenotype with
specific features, most importantly left ventricular cardiac hypertrophy. The majority of NSML cases result
from mutations in PTPN11, the gene encoding the non-receptor tyrosine phosphatase Shp-2. NSML shares
similar phenotypic features with familial sarcomeric forms of hypertrophic cardiomyopathy (HCM) including
hypertrophy, hypercontractility, arrhythmias, and risk of sudden death. 
By evaluating the underlying mechanisms of hypertrophy in a transgenic mouse model of NSML, which in
humans results in a particularly aggressive form of cardiac hypertrophy (Q510E), we sought to critically
evaluate the hypertrophy seen with NSML in hopes that mechanistic understanding of the disease can lead
to early diagnosis and intervention for NSML and HCM patients. We hypothesized that NSML hearts
demonstrate early hypercontractility secondary to an expanded contractile apparatus due to increased
transcription of mRNA and subsequent translation into protein. Additionally, we hypothesized that Q510E
mutants demonstrate increased PKA activity relative to non-transgenic littermates, which further augments
hypercontractility. The results show that transgenic mouse hearts have increased sarcomere density when
compared with nontransgenic littermates. mRNA expression is not increased, suggesting Shp-2 may be
important for sarcomere regulation and turnover. PKA activity is not a contributing factor to
hypercontractility.
